Sandoz responds to increased demand for antibiotics and other essential medicines for patients during COVID-19
With millions of patients affected by COVID-19, the raging pandemic has put enormous pressure on critical medicine safety stocks. Healthcare workers are using every tool available to treat COVID-19 and related (or secondary) infections, resulting in a heavy pull on several medicines, including antibiotics. The pull on the system has been significant with increased demand for key medicines from patients and governments.
Responding to these challenges, Sandoz, the Novartis generics and biosimilars division, has expanded its manufacturing capacity to maintain a stable supply of generic medicines for patients, while also delivering on a number of additional commitments to contribute to the global COVID-19 response. ?We are proud that we have so far managed to ensure a dependable supply of medicines through swift action to increase production in the face of rapidly surging demand and multiple new obstacles throughout the supply chain,? said Richard Saynor, Sandoz CEO. ?This crisis is exceptional, both in how it impacts our patients and the complexity it presents to us in how we respond. This is because we see a demand surge combined with major supply restrictions. The lockdown of borders and limitations on trade, export and air traffic, as well as the additional demands placed on employees both at sites and elsewhere, have made the production and delivery of medicines incredibly hard. Despite these challenges, we continue to deliver quality generic and biosimilar medicines to those patients we serve, while also meeting additional commitments to fight COVID-19.? Sandoz, the single largest medicines provider in Europe and a leading player globally, took early action to ensure patients could access its portfolio of medicines, despite the crisis. Measures such as proactive increases in inventory of antibiotics and respiratory medicines are now helping the company navigate COVID-related supply chain issues and continue to meet patient needs. All Sandoz manufacturing sites and suppliers have continued full production and delivery throughout this crisis. In addition to this, Sandoz committed in February to ensuring stable pricing for a basket of its essential medicines, which may help to treat COVID-19 patients. Sandoz is also supplying public and private partners with donations of a malaria drug with antiviral properties, currently being investigated as a potential treatment for COVID-19.? Novartis has committed to donate 130 million doses of this potential treatment, world-wide, based on government requests.We are proud that we have so far managed to ensure a dependable supply of medicines through swift action to increase production in the face of rapidly surging demand and multiple new obstacles throughout the supply chain.
- ?Sandoz employees around the globe are the reason we are able to meet the needs of patients, healthcare providers, and researchers at this time of global crisis,? said Richard Saynor. ?Without their willingness to work harder, problem solve faster, and collaborate in new ways, we would not be able to contribute in all the ways we are now.?
-